Director's share transfer

RNS Number : 5440J
Angle PLC
31 March 2010
 



 

ANGLE plc ("the Company")

 

Director's share transfer

 

ANGLE plc ("ANGLE"), the international venture management company focusing on the commercialisation of technology and the development of technology-based industry, announces that it has received notification from Andrew Newland, Chief Executive of ANGLE, regarding the transfer of ordinary shares of 10p each ("Ordinary Shares") in the Company.

 

The Company was informed today that, on 26 March 2010, Andrew Newland, Chief Executive of ANGLE, and his wife Mrs Harriet Newland transferred the following Ordinary Shares into Mr Newland's personal pension fund at a price of 36.75 pence per share, off market.

 

Ordinary shares were transferred as follows:

 

- 28,707 Ordinary Shares from Mr Newland to Mr Newland's personal pension fund; and - 28,707 Ordinary Shares from Mrs Newland to Mr Newland's personal pension fund.

 

There is no change to Mr Newland's beneficial interest in the Company, which following this notification remains at 7,054,686 Ordinary Shares representing 26.00 per cent. of the Company's issued share capital.  

 

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 


Collins Stewart Europe Limited

Stewart Wallace

 

0207 523 8350

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

 

 

Notes to Editors

 

ANGLE plc 

 

Founded in 1994, ANGLE is an international venture management company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients. 

 

ANGLE's specialist Management services business provides support on a fee-for-service basis to major clients around the world involved in incubation, IP commercialisation, SME innovation and growth and the operation of science & technology parks.

 

ANGLE also owns a portfolio of companies with high growth potential in the medical and technology sectors in both the UK and the US.  These have been developed whilst subsidiaries of ANGLE using its proprietary Progeny® process.  ANGLE seeks to retain a substantial shareholding in these companies with a view to ongoing returns from dividend, milestone, royalty and capital returns.   

 

ANGLE's venture management and technology commercialisation skills are of increasing relevance as global economies focus on regeneration, innovation and value added components to their industries.  ANGLE's technology skills in IT and software, medical and life sciences, clean tech and renewable energies are directly relevant to major growth markets of the future and are marketed as specialised Management services. 

 

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFISVEILVII

Companies

Angle (AGL)
UK 100